On September 14, 2020 At the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, which will be held virtually from 17th to 19th of September, PharmaMar (MSE:PHM) reported that it will present data on lurbinectedin in second-line SCLC patients who had received previous platinum-based chemotherapy and relapsed 90 and 180 days after its completion and therefore, being candidates for platinum re-challenge (Press release, PharmaMar, SEP 14, 2020, View Source [SID1234565098]). Phase I results for lurbinectedin in Japanese patients with previously treated advanced Solid Tumours, will also be presented.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Results of trabectedin in combination with immunotherapy (durvalumab) in pre-treated patients with advanced Soft-Tissue Sarcomas, will be presented at an oral session.
In addition, results of Yondelis (trabectedin) in combination with immunotherapy (nivolumab) for the treatment of Soft-Tissue Sarcoma, as well as results of trabectedin in combination with doxorubicin (PLD) for the treatment of Recurrent Ovarian Cancer, will be presented.
ZepzelcaTM (lurbinectedin)
The poster, titled "Activity of Lurbinectedin in Second-line SCLC Patients Candidates for Platinum Re-challenge" will present the evaluation of a subset of patients from the Phase II basket trial, conducted both in the United States and in Europe, in which 105 patients with SCLC who had progressed after previous platinum-based chemotherapy, participated.
In the 20 patients who were platinum-sensitive and had a CTFI (Chemotherapy-Free Interval) of more than 180 days and were, therefore, candidates for platinum re-challenge according to National Comprehensive Cancer Network guidelines (NCCN), an overall survival of 16.2 months and an Overall Response Rate (ORR) of 60% were achieved.
A poster on a Phase I trial of lurbinectedin in Japanese patients with advanced solid tumours will also be presented.
Yondelis (trabectedin)
During this ESMO (Free ESMO Whitepaper) Congress, different studies carried out with Yondelis (trabectedin) will be presented, including an oral presentation by the French Sarcoma Group on late breaking results of trabectedin in combination with durvalumab in pre-treated patients with advanced Soft-Tissue Sarcomas.
Data from a non-randomised, open-label, phase II trial, assessing the efficacy and feasibility of the treatment with trabectedin in combination with nivolumab, in patients with metastatic or inoperable Soft-Tissue Sarcomas after anthracycline treatment, will be presented as a poster.
Moreover, a sub-analysis of a randomised, phase III study, comparing trabectedin in combination with pegylated liposomal doxorubicin (PLD) versus PLD monotherapy, in patients with recurrent Ovarian Cancer, will also be presented as a poster.
Finally, as an oral presentation, results of the InovatYon study -an international, randomised, phase III study comparing PLD with either trabectedin or carboplatinum in patients with recurrent Ovarian Cancer, progressing 6-12 months after the last platinum line– will be presented.
The studies presented at the ESMO (Free ESMO Whitepaper) 2020 congress are available at:
View Source
Outstanding studies in ESMO (Free ESMO Whitepaper) 2020
ZepzelcaTM (lurbinectedin)
Activity of Lurbinectedin in Second-line SCLC Patients Candidates for Platinum Re-challenge
E-Poster Display session. 17.09.2020. 09:00 – 23:59, Channel: On-Demand
Main author: Subbiah V et al.
Phase I study of lurbinectedin in Japanese patients with pretreated advanced tumors: Final results
E-Poster Display session. 17.09.2020. 09:00 – 23:59, Channel: On-Demand
Main author: Takahashi et al.
Yondelis (trabectedin)
Randomized, phase III international study to evaluate whether the administration of trabectedin/PLD followed by platinum at progression could improve overall survival in comparison with a platinum-based regimen in patients with recurrent ovarian cancer and a platinum-free interval between 6-12 months
Oral session. 19.09.2020. 13:26 – 13:38.
Presentation number: LBA30
Main author: Nicoletta Colombo (Milan, Italy)
TRAMUNE, a phase Ib study combining Trabectedin and Durvalumab: Results of the expansion cohort in patients with advanced pretreated Soft Tissue Sarcomas
Oral session. 20.09.2020, 16:32 – 16:44.
Presentation number: LBA67
Main author: Maud Toulmonde (Bordeaux, CEDEX, France)
Treatment: trabectedin in inmunotherapy + durvalumab
Subanalysis of a randomized phase 3 study comparing trabectedin and PLD vs PLD alone in patients with recurrent ovarian cancer (ROC)
E-Poster Display session. 17.09.2020. 09:00 – 23:59, Channel: On-Demand
Main author: Monk, Herzog, Coleman
A non-randomized, open-label phase II trial evaluating efficacy and feasibility of combined treatment with trabectedin and nivolumab in patients with metastatic or inoperable soft tissue sarcomas after failure of an anthracycline-containing regimen.
E-Poster Display session. 17.09.2020. 09:00 – 23:59, Channel: On-Demand
Main author: Pink et al.
Treatment: trabectedin in inmunotherapy + nivolumab
Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About Yondelis
Yondelis (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.
About lurbinectedin
Lurbinectedin (ZepzelcaTM), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinacidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.